focus -WSS

focus

author：focus 2025-09-06 02:06:44 - browse：257

Doctor holding a clipboard. -- health coverage from STAT — Adobe

The momentum around weight loss drugs is about to get even bigger in the wake of Novo Nordisk’s announcement that its semaglutide drug Wegovy cut the risk of cardiovascular disease by 20% in its large SELECT trial.

The full results of the study, funded by Novo, will be presented at the American Heart Association meeting in November. Doctors and researchers say they expect the findings to have a big impact on how clinicians approach the treatment of both obesity and cardiovascular disease, as well as increase the likelihood that prescriptions for obesity drugs will be covered by insurance.

But experts who spoke with STAT also cautioned that the long-term safety and efficacy of Wegovy and other weight loss drugs remain unknown. The SELECT study has yet to be peer-reviewed, and not enough information is yet available to make independent assessments of the results.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Medicare Advantage plans can’t deny care with AI, CMS warns

WSS

Top private equity targets in 2023: cardiology, clinical trials, lasers

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Researchers tackle phage therapy hurdles for wider adoption

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Measles policy set amid Florida outbreak alarms vaccine proponents

AstraZeneca stays mum on Medicare drug pricing negotiations

leisure time

focus

focus

How one medical school became remarkably diverse

New CMS data security rules will hurt Medicare, Medicaid research

BioMarin wins approval for gene therapy to treat hemophilia A

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

As demand for Covid shots wanes, Moderna seeks its next success

As AI regulations shape up, health tech startups beg for clarity

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Opioid cravings were reduced by anti

Heart attack and stroke risk calculators need revising

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

leisure time

A single Democrat is willing to weaken Medicare negotiation power

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Devoted Health’s losses in Medicare Advantage persist

Secretariat’s lessons for human medicine

Measles policy set amid Florida outbreak alarms vaccine proponents

entertainment

explore

hotspot

focus